(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21597 A1

(51) International Patent Classification⁷: C07D 239/94, 401/12, 403/12, A61K 31/517, A61P 35/00

(21) International Application Number: PCT/GB00/03593

(22) International Filing Date:
19 September 2000 (19.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9922171.5 21 September 1999 (21.09.1999) GB

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MORTLOCK, Andrew, Austen** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **KEEN, Nicholas, John** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **BRYANT, Tracey**; Astrazeneca, Global Intellectual Property, Alderley Park, P.O. Box 272, Mereside, Macclesfield, Cheshire SK10 4GR (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC QUINAZOLINE DERIVATIVES



(I)

(57) Abstract: A compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O), $S(O)_2$ or NR^6 where R^6 is hydrogen of C_{1-6}alkyl; R^5 is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R^1, R^2, R^3, R^4 are independently selected from halogeno, cyano, nitro, C_{1-3}alkylsulphanyl, $-N(OH)R^7$-(wherein R^7 is hydrogen, or C_{1-3}alkyl), or R^9X^1-(wherein X^1represents a direct bond, -O-, $-CH_2$-, -OC(O), -C(O)-, -S-, -SO-, $-SO_2$-, $-NR^{10}C(O)$-, $-C(O)NR^{11}$-, $-SO_2NR^{12}$-, $-NR^{13}SO_2$- or NR^{14}-(wherein R^{10}, R^{11}, R^{12}, R^{13} and R^{14} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl), and R^9 is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; provided that at least one of R^2 or R^3 is other than hydrogen. These compounds inhibit aurora 2 kinase and are useful in the preparation of medicaments for the treatment of proliferative disease such as cancer.

WO 01/21597 A1